Research programme: galectin inhibitors - Galectin Therapeutics
Alternative Names: GM series; GM-CT-02; GR series; GR-MD-01; PRO-GR 300Latest Information Update: 28 Apr 2022
At a glance
- Originator Pro-Pharmaceuticals
- Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai
- Class Antifibrotics; Antineoplastics; Carbohydrates; Hepatoprotectants
- Mechanism of Action Galectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Fibrosis; Hepatic fibrosis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in USA (PO)
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in USA (SC)